Market research
GNTA Genenta Science SpA ADR
NASDAQ USD Industrials
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 41M
- P/E ratio
- Not available
- Analyst target
- 6.9801
- Dividend yield
- Not available
- Beta
- 0.72
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Industrials
- Industry
- Conglomerates
- ISIN
- US36870W1009
- Market cap
- 41M
- P/E ratio
- Not available
- Analyst target
- 6.9801
- Dividend yield
- Not available
- Beta
- 0.72
About
About Genenta Science SpA ADR
Genenta Science S.p.A., develops hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. The company offers Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. It is developing Temferon for use in the treatment of other solid tumor indications. In addition, the company develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages. Additionally it designs, engineers and manufactures high-precision tactical rifles, chassis systems, optics mounts, bipods, and related accessories. It also builds critical mechanical components for space and defense systems. Genenta Science S.p.A. was incorporated in 2014 and is headquartered in Milan, Italy.
Visit company websiteCommunity
Investor discussion
0 comments
Sign in to join the GNTA discussion.
No comments yet
Start a focused discussion about GNTA.